$CIFR Extremely oversold in the Long Term Smart Money Buy Zone
I am not taking this since I just tagged out of my short term position at $9
That said, this is an amazing zone to load up if I wanted to own it long term
Morgan Stanley's $CIFR valuation: $18/share based on existing leases and Bitcoin mining assets, rising to $51.50/share if additional sites secure data center lease agreements. At $6.45, that's the best asymmetric bet in the AI infrastructure space.
DON'T JUST BUY STOCKS BECAUSE THEY'RE DOWN 50%.
Buy companies where earnings are accelerating.
Top 10 names worth watching.
1. $MU | One of the world's largest memory chip manufacturers, generating $133.2B in FY2026 revenue
These AI stocks are trading near their lowest valuations in company history!
$SNDK — 3.3×
$SMCI — 5.0×
$FPS — 14.4×
$AAOI — 15.0×
$CRDO — 16.5×
$AMZN — 25.2×
$ALAB — 27.7×
$GEV — 33.2×
All forward PE valuation.
Value trap or a bargain? 👀
$NOK's optical marketing head told Fierce Network on 6 November that "anything that involves a laser" belongs on Nokia's list, the same lasers $COHR and $LITE grow for AI racks.
Rob Shore said Nokia is still testing near-packaged and co-packaged optics. He also said it is safe to say Nokia will get into that market.
Dell'Oro puts 30 to 40% of pluggable-optic power on the DSP chip alone. Take the DSP out and the rack uses less power and less cooling.
Shore expects near-packaged optics to win more of the market than co-packaged. Nokia is expanding San Jose manufacturing and the plant it bought from NXP in August to feed that demand.
Nokia already owns the indium phosphide fab from the $2.3B Infinera deal. Now its own optical team is saying out loud that it wants the laser slot inside the rack.
$OSCR
back down.
Price is back within the trend channel.
This was a bearish fakeout,
we will watch closely, whether we see a contact or a break at the rising support.
A break below and towards the $21 just became more likely.
$OSCR pt $78.
This is not investment advice.
https://t.co/ojrZjaKVWh
$ETON +17% at open today 🚀
Two updates landed together: record Q3 product sales of $57.9M (+158% YoY) and preliminary ET-700 pilot data in Wilson disease.
See which biotech catalysts we flag as potential big movers in our FREE report 👇
https://t.co/g8sMZ9xwJM